This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Surgery  • Surgical Interventions  • Endocrine Surgery  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2004;292:1946.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Researchers from 12 medical centers have published the first annual report of the Collaborative Islet Transplant Registry, results from islet cell transplants at centers in the United States, Canada, and Europe. The project was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, in Bethesda, Md. The report provides information on islet cell transplants in 86 patients with type 1 diabetes and analyzes factors that can affect the outcome of this experimental procedure (http://www.citregistry.org).

At 6 months after the last infusion, 61% of recipients no longer needed to inject insulin; 1 year after the last transfusion, 58% were still able to forgo insulin treatment. Researchers plan to continue monitoring patients.

The centers reported 45 serious adverse events but no deaths. Life-threatening events included those linked to the transplant procedure itself and to immunosuppressive medications. Serious adverse events related to islet infusion included . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?